HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Hepatocellular adenoma — Clinical Guidelines

Overview

Hepatocellular adenoma (HCA) is a rare benign liver tumor predominantly found in young to middle-aged women, often associated with oral contraceptive use or other steroid medications. It carries risks of bleeding and potential malignant transformation, particularly in β-catenin-mutated subtypes. 3

Diagnosis

Imaging: Magnetic resonance imaging (MRI) with hepato-specific contrast agents is superior for detecting HCAs and subtyping them, achieving up to 80% accuracy and >90% specificity for identifying 1α-mutated or inflammatory HCAs. 3

Subtypes: Pathological classification includes hepatocyte nuclear factor 1α-mutated, inflammatory, β-catenin-mutated, and unclassified HCAs, with β-catenin-mutated having the highest risk of complications. 3

Management

Surgical Resection: Primary treatment often involves surgical resection for definitive management.

Radiofrequency Ablation (RFA): Effective for localized HCAs, with successful ablation reported in hepatocellular cancer management, though specific dosing and protocols for HCAs are not detailed here. 4

Monitoring: Regular imaging follow-up is essential, especially given the risk of recurrence or transformation. 3

Special Populations

Pregnancy: Not specifically addressed in the provided abstracts.

Elderly: No specific considerations mentioned.

Comorbidities: Management considerations for comorbidities like hypertension (common with TKI use) are not directly linked to HCA management in the provided abstracts. 1

Key Recommendations

Utilize MRI with hepato-specific contrast agents for accurate detection and subtyping of HCAs. (Evidence: Moderate) 3

Consider surgical resection as the primary treatment modality for definitive management of HCAs. (Evidence: Expert opinion)

Implement regular imaging follow-up post-treatment to monitor for recurrence or transformation. (Evidence: Expert opinion)

References

1 Lai X, Wan Q, Jiao SF, Sun XC, Hu JF, Peng HW. Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study. Expert opinion on drug safety 2024. link 2 Wilson DB, Rudnick DA. Invasive Ductular Reaction: Form and Function. The American journal of pathology 2019. link 3 Renzulli M, Clemente A, Tovoli F, Cappabianca S, Bolondi L, Golfieri R. Hepatocellular adenoma: An unsolved diagnostic enigma. World journal of gastroenterology 2019. link 4 Gulati MS, Batra Y, Paul SB, Madan K, Ahuja V, Kaul HK. Radiofrequency ablation: a new therapeutic modality for the management of hepatocellular cancer. Tropical gastroenterology : official journal of the Digestive Diseases Foundation 2002. link

Hepatocellular adenoma